for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca plc

AZN.L

Latest Trade

7,203.00GBp

Change

76.00(+1.07%)

Volume

1,505,027

Today's Range

7,066.00

 - 

7,236.00

52 Week Range

5,312.00

 - 

7,583.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
7,127.00
Open
7,089.00
Volume
1,505,027
3M AVG Volume
37.90
Today's High
7,236.00
Today's Low
7,066.00
52 Week High
7,583.00
52 Week Low
5,312.00
Shares Out (MIL)
1,311.88
Market Cap (MIL)
91,370.04
Forward P/E
23.85
Dividend (Yield %)
--

Next Event

Q3 2019 AstraZeneca PLC Earnings Release

Latest Developments

More

Ironwood Pharmaceuticals, AstraZeneca Amend Linzess Collaboration In China

Mylan Expands Oncology Portfolio With Launch Of Generic Faslodex Injection

FDA Grants Fast Track Designation For FARXIGA In Heart Failure

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Industry

Biotechnology & Drugs

Contact Info

1 Francis Crick Avenue

+44.20.73045000

https://www.astrazeneca.com/Home

Executive Leadership

Leif Johansson

Independent Non-Executive Chairman of the Board

Pascal Soriot

Chief Executive Officer, Executive Director

Marc Dunoyer

Chief Financial Officer, Executive Director

Katarina Ageborg

Executive Vice President - Sustainability, Chief Compliance Officer

Fiona Cicconi

Executive Vice President - Human Resources

Key Stats

2.30 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

23.0K

2017

22.5K

2018

22.1K

2019(E)

23.9K
EPS (USD)

2016

4.310

2017

4.280

2018

3.460

2019(E)

3.610
Price To Earnings (TTM)
50.40
Price To Sales (TTM)
4.94
Price To Book (MRQ)
8.41
Price To Cash Flow (TTM)
19.48
Total Debt To Equity (MRQ)
145.44
LT Debt To Equity (MRQ)
131.89
Return on Investment (TTM)
4.80
Return on Equity (TTM)
3.38

Latest News

AstraZeneca diabetes drug granted fast track status for heart failure treatment

AstraZeneca's diabetes drug, Farxiga, has been granted fast track designation by U.S. regulators for the treatment of heart failure, boosting prospects of wider use of the drug and putting it ahead of rivals.

AstraZeneca's Farxiga granted fast track status for heart failure treatment

AstraZeneca Plc said on Monday the U.S. Food and Drug Administration (FDA) had granted fast track designation for the development of its diabetes drug Farxiga to reduce the risk of deadly heart attacks in some patients.

AstraZeneca's Imfinzi prolongs survival in aggressive lung cancer

AstraZeneca's cancer treatment Imfinzi has been shown to prolong survival in a particularly aggressive type of lung cancer by close to three months, as the British drugmaker holds its ground in a crowded field against rival immunotherapy drugs.

AstraZeneca's Tagrisso helps lung cancer patients live longer: study

(Corrects Aug. 9 story to show study points to overall survival and not progression free survival in first paragraph)

CORRECTED-UPDATE 1-AstraZeneca's Tagrisso helps lung cancer patients live longer- study (Aug. 9)

AstraZeneca Plc said on Friday a late-stage study showed its top-selling drug, Tagrisso, had significantly helped patients with a type of lung cancer live longer.

AstraZeneca's Tagrisso gets China OK for type of lung cancer

AstraZeneca Plc <AZN.L> said on Wednesday it had received marketing authorisation from China's National Medical Products Administration for its top-selling drug, Tagrisso, to treat adults with a form of lung cancer.

AstraZeneca lupus drug shows promise after set-back last year

AstraZeneca Plc said on Thursday its experimental drug to treat moderate-to-severe lupus met the main goal in a late-stage study, an encouraging sign after it failed to meet its main target in the final stage of another trial last year.

AstraZeneca lupus drug meets main goal in study

AstraZeneca Plc said on Thursday its experimental drug to treat moderate-to-severe lupus, anifrolumab, met its main goal in a late-stage study.

AstraZeneca respiratory business gets boost from three-drug inhaler results

Prospects for AstraZeneca's <AZN.L> respiratory treatments business improved on Wednesday as a three-drug inhaler was shown to ease smoker's lung and U.S. regulators granted its injectable asthma drug Fasenra special status for a rare lung condition.

U.S. FDA grants orphan drug status to AstraZeneca's asthma drug Fasenra

AstraZeneca said on Wednesday that the U.S. Food and Drug Administration has granted orphan drug status to its severe asthma drug, Fasenra, to treat eosinophilic oesophagitis (EoE).

FDA gives fast track status to AstraZeneca's diabetes drug Farxiga

AstraZeneca Plc said on Tuesday that the U.S. Food and Drug Administration has granted fast track status for the development of its diabetes drug Farxiga to prevent heart and kidney failure in patients with chronic kidney disease (CKD).

AstraZeneca says U.S. FDA grants fast track status for diabetes drug Farxiga

AstraZeneca Plc said on Tuesday that the U.S. Food and Drug Administration granted fast track status for the development of its diabetes drug Farxiga to prevent heart and kidney failure in patients with long-term kidney disease.

AstraZeneca Imfinzi combination fails advanced lung cancer study

A combination of AstraZeneca's lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations, the drugmaker said on Wednesday.

CORRECTED-UPDATE 1-AstraZeneca's Imfinzi combination fails advanced lung cancer study

AstraZeneca said on Wednesday a combination treatment including its lung cancer drug Imfinzi failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations.

AstraZeneca's Imfinzi misses main goal of advanced lung cancer study

London-listed drugmaker AstraZeneca Plc said on Wednesday its immunotherapy treatment Imfinzi did not meet the main goal of a late-stage study for advanced non-small cell lung cancer.

UPDATE 2-European shares end lower as Italy's political crisis weighs

* Pandora tops STOXX 600 after keeping FY forecast (Recasts, changes comments; Updates to close)

Worries over global trade, Italy lead FTSE 100 lower

London's main index ended firmly in the red on Tuesday after new U.S.-China trade jitters and political instability in Italy took down heavyweight firms across sectors, while exporter stocks dipped as the pound gained after German Chancellor Angela Merkel's comments on the...

AstraZeneca diabetes drug shows promise in heart failure

AstraZeneca <AZN.L> made strides on Tuesday towards its goal of adding heart failure to the conditions that can be treated by its diabetes drug Farxiga, putting it ahead of a rival medicine from Eli Lilly <LLY.N>.

FTSE 100 edges up on AstraZeneca boost

London's FTSE 100 inched higher in early deals on Tuesday, as AstraZeneca advanced after its diabetes drug Farxiga met the main goal of a heart failure study, offsetting a post-earnings drop for miner BHP.

European shares rise for third straight session

European shares rose for the third straight session on Tuesday, building on a recovery since late last week as British drugmaker AstraZeneca surged on results of a late-stage study.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up